GRAL

GRAIL, Inc. NASDAQ Listed Jun 12, 2024

Healthcare ·Services-Medical Laboratories ·US · grail.com

$62.92

Pre-mkt $64.36 +2.29%

Mkt Cap $2.6B

52w Low $29.95 37.1% of range 52w High $118.84

50d MA $50.88 200d MA $67.11

P/E (TTM) -4.9x

EV/EBITDA -7.9x

P/B 0.8x

Debt/Equity 0.0x

ROE -15.8%

P/FCF -10.5x

RSI (14) —

ATR (14) —

Beta 4.64

50d MA $50.88

200d MA $67.11

Avg Volume 1.3M

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

SIC Code

8071

CIK (SEC)

1699031

Phone

(833) 694-2553

1525 O'BRIEN DRIVE · MENLO PARK, CA 94025 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
May 5, 2026	AMC	-2.76	-2.29	+17.1%	54.40	+2.9%	+15.3%	+15.7%	—	—	—	—
Feb 19, 2026	AMC	-3.33	-2.44	+26.7%	101.53	-51.1%	-50.5%	-57.6%	-50.4%	-49.0%	-42.8%	—
Nov 12, 2025	AMC	-3.36	-2.46	+26.8%	84.77	+1.6%	-1.9%	-6.1%	+0.2%	-3.9%	+3.8%	—
Aug 12, 2025	AMC	-3.14	-3.18	-1.3%	33.60	-3.2%	+1.1%	-4.2%	-3.5%	-2.4%	-6.5%	—
May 13, 2025	AMC	-4.03	-3.10	+23.1%	42.89	-12.8%	-23.3%	-9.1%	-6.9%	-10.9%	-8.3%	—
Feb 20, 2025	AMC	-4.41	-1.86	+57.8%	47.76	+2.6%	-14.7%	-5.2%	-9.7%	-8.1%	-17.8%	—
Nov 12, 2024	AMC	-6.43	-3.94	+38.7%	15.09	-1.6%	+5.5%	+4.8%	-1.9%	-7.2%	-2.0%	—
Aug 13, 2024	AMC	—	-5.30	—	15.84	+12.8%	-2.8%	+0.2%	+5.7%	+6.0%	+1.4%	—
Mar 31, 2024	AMC	—	-7.05	—	—	—	—	—	—	—	—	—
Dec 31, 2023	AMC	—	-0.18	—	—	—	—	—	—	—	—	—
Sep 30, 2023	AMC	—	-28.71	—	—	—	—	—	—	—	—	—
Jun 29, 2023	AMC	—	-6.22	—	—	—	—	—	—	—	—	—
Apr 2, 2023	AMC	—	-6.24	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 30	Guggenheim	Maintains	Buy → Buy	—	$48.49	$49.00	+1.1%	-3.3%	+6.6%	+10.5%	+13.4%	+6.7%
Feb 24	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$43.03	$42.71	-0.7%	+17.0%	+20.4%	+35.0%	+23.7%	+22.3%
Feb 20	Baird	Maintains	Outperform → Outperform	—	$101.53	$49.66	-51.1%	-50.5%	-57.6%	-50.4%	-49.0%	-42.8%
Feb 20	Canaccord Genuity	Maintains	Buy → Buy	—	$101.53	$49.66	-51.1%	-50.5%	-57.6%	-50.4%	-49.0%	-42.8%
Jan 26	Guggenheim	Maintains	Buy → Buy	—	$104.90	$104.51	-0.4%	+1.3%	+3.9%	-3.7%	-3.7%	-6.7%
Dec 2	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$98.27	$99.44	+1.2%	-0.9%	+3.0%	+6.6%	+2.8%	+1.6%
Nov 17	Canaccord Genuity	Maintains	Buy → Buy	—	$79.63	$79.20	-0.5%	+6.7%	+2.3%	+10.5%	+7.6%	+17.5%
Nov 12	Guggenheim	Upgrade	Neutral → Buy	—	$83.39	$88.57	+6.2%	+1.7%	-0.2%	-4.5%	+1.9%	-2.3%
Oct 22	Canaccord Genuity	Maintains	Buy → Buy	—	$83.71	$83.89	+0.2%	-4.7%	-1.3%	+6.8%	+1.5%	+3.2%
Oct 3	Canaccord Genuity	Maintains	Buy → Buy	—	$64.73	$67.00	+3.5%	+1.3%	-4.7%	-3.0%	+12.5%	+9.9%
May 14	Canaccord Genuity	Maintains	Buy → Buy	—	$42.89	$37.40	-12.8%	-23.3%	-9.1%	-6.9%	-10.9%	-8.3%
Mar 18	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$29.13	$29.19	+0.2%	-3.3%	-3.8%	-4.5%	+4.0%	+10.3%

Data updated apr 25, 2026 12:13pm · Source: massive.com